

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6206963

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CELGENE CORPORATION	07/07/2020
CELGENE ALPINE INVESTMENT COMPANY, II LLC	07/07/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NOGRA PHARMA LIMITED
<b>Street Address:</b>	33 SIR JOHN ROGERSON'S QUAY
<b>City:</b>	DUBLIN 2
<b>State/Country:</b>	IRELAND
<b>PROPERTY NUMBERS Total: 15</b>	
<b>Property Type</b>	<b>Number</b>
PCT Number:	EP1574070
Application Number:	16601905
Application Number:	62235556
PCT Number:	EP1673518
PCT Number:	US1719094
PCT Number:	IB1465421
Application Number:	62097012
Application Number:	62235269
PCT Number:	US1500269
PCT Number:	US1567612
Application Number:	62235475
Application Number:	62360256
PCT Number:	US1654734
Application Number:	62538504
PCT Number:	US1843867
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-570-1000

**Email:** US-patentbos@goodwinlaw.com, kbranzetti@goodwinlaw.com, AMingLum@goodwinlaw.com, YCai@goodwinlaw.com  
**Correspondent Name:** GOODWIN PROCTER LLP / PATRENT ADMINISTRATOR  
**Address Line 1:** 100 NORTHERN AVENUE  
**Address Line 4:** BOSTON, MASSACHUSETTS 02210

**ATTORNEY DOCKET NUMBER:** GIU-041,48,53,63,64,65,66

**NAME OF SUBMITTER:** BRIAN A. FAIRCHILD

**SIGNATURE:** /Brian A. Fairchild/

**DATE SIGNED:** 07/17/2020

**Total Attachments: 8**

source=Confirmatory Assignment (Celgene owned or co-owned)#page1.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page2.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page3.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page4.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page5.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page6.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page7.tif  
source=Confirmatory Assignment (Celgene owned or co-owned)#page8.tif

## CONFIRMATORY ASSIGNMENT

**THIS CONFIRMATORY ASSIGNMENT**, made by Celgene Corporation, a corporation organized under and pursuant to the laws of Delaware having its principal place of business at 86 Morris Avenue, Summit, New Jersey 07901, and/or Celgene Alpine Investment Company II, LLC, a limited liability company organized under and pursuant to the laws of Delaware having its principal place of business at Aon House, 30 Woodbourne Ave, Pembroke, HM 08, Bermuda (the "Assignors");

**WHEREAS**, Assignors were the owners or co-owners, by assignment, of the Patent Applications listed in Schedule A (the "Applications") and the inventions described and/or claimed in the Applications (the "Inventions");

**WHEREAS**, Nogra Pharma Limited, a corporation organized under and pursuant to the laws of Ireland having its principal place of business at 33 Sir John Rogerson's Quay, Dublin 2, IRELAND (the "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Inventions and said Applications, and in and to any letters patent to be obtained therefore and thereon; and

**WHEREAS**, Assignors and Assignee wish to confirm in writing that, Assignors assigned and transferred to Assignee their entire right, title and interest in and to the Inventions and Applications pursuant to the Program Transfer Agreement dated April 7, 2020.

**NOW, THEREFORE**, to all whom it may concern be it known that this Confirmatory Assignment confirms that for good and sufficient consideration already provided, the receipt of which is hereby acknowledged, Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, Assignors' entire right, title and interest in and to the Inventions and Applications, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said Applications, and any and all letters patent in the United States and all foreign countries and regions which may be granted therefore and thereon, and reissues, reexaminations and extensions of said letters patent, and all rights under any and all United States laws and foreign and international agreements, treaties or laws relating to the protection of industrial property, including but

not limited to any cause(s) of action and damages accruing prior to this assignment, including all rights to exclude others from practicing the claimed inventions and all rights to seek any and all remedies in law or equity, including damages and injunctive relief, for past, present, and future infringement, and the right to claim priority from the Applications for any such applications and letters patent (collectively, the "Patent Rights"), the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made;

**AND**, Assignors hereby confirm that, at the time of execution of the Program Transfer Agreement, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignors were the lawful owner of the entire or partial right, title and interest in and to the Inventions and Patent Rights above-mentioned, and that the same were unencumbered and that Assignors had good and full right and lawful authority to sell and convey the same;

**AND**, Assignors hereby confirm and agree to and with Assignee, its successors, legal representatives and assigns, that Assignors will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done to effectuate the transfer of the Inventions and Applications at Assignee's expense;

**AND** Assignors hereby confirm, authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Letters Patent as shall be granted upon said Applications, or applications based thereon, to Assignee, its successors, legal representatives and assigns;

**AND** Assignors hereby grant the following individuals the power to insert on this Confirmatory Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

GOODWIN PROCTER LLP

All practitioners at Customer Number 051414.

**IN TESTIMONY WHEREOF**, Assignors and Assignee have caused this Confirmation of Assignment to be duly executed on the date(s) set forth below, where Assignors and Assignee may execute this Confirmatory Assignment in counterparts, in which case each executed counterpart will be considered to be an original.

ASSIGNOR: Celgene Corporation

  
Signature

July 7, 2020  
Date

**Denise Hickey**  
Printed Name


**Authorized Signatory/VP &  
Assistant General Counsel,  
Bristol-Myers Squibb Company**  
Title

Witness:

July 7, 2020  
Date

  
Sara Hart

ASSIGNOR: Celgene Alpine Investment Company, II LLC

  
Signature

July 7, 2020

Date

**Denise Hickey**

Printed Name

**Authorized Signatory/VP &  
Assistant General Counsel,  
Bristol-Myers Squibb Company**

Title

Witness:

July 7, 2020

Date



Sara Hart

ASSIGNEE does hereby acknowledge and accept receipt of the entire right, title and interest in and to the INVENTIONS AND PATENT RIGHTS.

Nogra Pharma Limited

By: Deke

Title: Director

Date: 16 July 2020



**SCHEDULE A**

<b>Application No.</b>	<b>Attorney Docket No.</b>	<b>Filing Date</b>	<b>Inventor</b>	<b>Title</b>	<b>Country</b>
PCT/EP15/74070	GIU-041PC	Oct 16, 2015	Giovanni Monteleone et al.	METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS	PCT
15/519,489	GIU-041	Apr 14, 2017	Giovanni Monteleone et al.	METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS	US
16/601,905	GIU-041C1	Oct 15, 2019	Salvatore Bellinvia	METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS	US
62/235,556	GIU-048PR	Sep 30, 2015	Salvatore Bellinvia et al.	METHODS OF USING SMAD7 ANTISENSE OGLIONUCLEOTIDES BASED ON BIOMARKER EXPRESSION	US
PCT/EP16/73518	GIU-048WO	Sep 30, 2016	Salvatore Bellinvia et al.	METHODS OF USING SMAD7 ANTISENSE OGLIONUCLEOTIDES BASED ON BIOMARKER EXPRESSION	PCT
15/764,567	GIU-048	Mar 29, 2018	Salvatore Bellinvia et al.	METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION	US
PCT/US17/19094	GIU-053WO	Feb 23, 2017	Giovanni Monteleone	METHODS OF TREATING INTESTINAL FIBROSIS USING SMAD7 INHIBITION	PCT

16/079,059	GIU-053	Aug 22, 2018	Giovanni Monteleone	METHODS OF TREATING INTESTINAL FIBROSIS USING SMAD7 INHIBITION	US
15/519,502	GIU-063	Apr 14, 2017	Peter Anthony Cicala	ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES	US
PCT/IB14/65421	GIU-063WO	Oct 17, 2014	Peter Anthony Cicala	ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES	PCT
62/097,012	GIU-064PR	Dec 26, 2014	Scott Andrew Smith et al.	METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES	US
62/235,269	GIU-064PR2	Sep 30, 2015	Scott Andrew Smith et al.	METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES	US
PCT/US15/00269	GIU-064WO	Dec 23, 2015	Scott Andrew Smith et al.	METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES	PCT
PCT/US15/67612	GIU-064WO2	Dec 28, 2015	Scott Andrew Smith et al.	METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES	PCT
15/539,497	GIU-064	Jun 23, 2017	Scott Andrew Smith et al.	METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES	US
62/235,475	GIU-065PR	Sep 30, 2015	Gerald Scott Barden Horan	TLR MODULATORS AND METHODS OF USE	US
62/360,256	GIU-065PR2	Jul 08, 2016	Gerald Scott Barden Horan	TLR MODULATORS AND METHODS OF USE	US
PCT/US16/54734	GIU-065WO	Sep 30, 2016	Gerald Scott Barden Horan	TLR MODULATORS AND METHODS OF USE	PCT
15/764,269	GIU-065	Mar 28, 2016	Gerald Scott Barden Horan	TLR MODULATORS AND METHODS OF USE	US
62/538,504	GIU-066PR	Jul 28, 2017	Anthony Frank et al.	METHOD OF PREPARING OLIGONUCLEOTIDE COMPOUNDS	US
PCT/US18/43867	GIU-066WO	Jul 26, 2018	Anthony Frank et al.	METHOD OF PREPARING OLIGONUCLEOTIDE COMPOUNDS	PCT
16/634,078	GIU-066	Jan 24, 2020	Anthony Frank et al.	METHOD OF PREPARING OLIGONUCLEOTIDE COMPOUNDS	US